Alpha-gal syndrome is a real, documented, CDC-recognized allergic condition. It is also one of the strangest conditions in modern medicine: a tick bite that teaches your immune system to reject red meat. That strangeness — combined with the geographic overlap with a documented federal bioweapon lab and the on-camera statements of the scientist who discovered Lyme disease — is what keeps it in the researcher conversation.
Where it started
The medical story begins in 2002. At the University of Virginia, immunologist Dr. Thomas Platts-Mills and colleagues — including Dr. Scott Commins, who later moved to the University of North Carolina, and Tina Hatley Merritt — were investigating anaphylactic reactions in patients receiving the colon-cancer drug cetuximab (marketed as Erbitux). The reactions were concentrated in specific patients and specific geographic regions, which made them unusual. The team discovered the reactions were caused by IgE antibodies to galactose-α-1,3-galactose ("alpha-gal") — a sugar molecule present in the cetuximab formulation because the drug is produced in mouse myeloma cells, and more broadly present in the tissues of most non-primate mammals.
The sensitization source remained unclear until geographic analysis showed cetuximab reactions concentrated in the southeastern US, matching almost exactly the established range of the Lone Star tick (Amblyomma americanum). In a turn that helped confirm the connection, Platts-Mills himself was bitten by a Lone Star tick during hiking fieldwork and subsequently developed the allergy — an unusually direct confirmation of the tick-bite mechanism, documented in the subsequent literature. The tick-bite-causes-meat-allergy connection was formally established in the 2009 paper "Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant," published in the Journal of Allergy and Clinical Immunology by Commins, Platts-Mills, and colleagues. This is the paper most researchers cite as the formal discovery of AGS as a distinct clinical entity.
The CDC first issued formal health advisories on AGS in the 2010s, and the first comprehensive Morbidity and Mortality Weekly Report on AGS case numbers — MMWR 72(30), titled "Geographic Distribution and Expansion of Human Alpha-Gal Syndrome — United States, 2010–2022" — was published on July 27, 2023. The MMWR documented more than 110,000 suspected cases, estimated actual prevalence at up to 450,000 Americans, and noted that suspected cases had more than doubled between 2017 and 2021. State health departments in several AGS-concentrated states have subsequently added it to reportable-disease lists. The first documented death attributed to AGS was published in 2024.
What the theory claims
The AGS researcher conversation operates on a different register from most frameworks on this site, because the underlying condition is scientifically accepted and mainstream-recognized. The contested claims are narrower and more specific: about origin, about the adjacent research-program history, about pharmaceutical implications, and about whether the condition's rising prevalence is purely ecological or partially instrumentalized by adjacent policy agendas.
The laboratory-origin framing. That the Lone Star tick's apparent sudden ability to induce alpha-gal sensitization in humans reflects either natural mutation within the last several decades or deliberate modification. Proponents point to the geographic overlap between AGS hotspots and the historical location of the Plum Island Animal Disease Center, an 840-acre federal biocontainment facility off the northeast tip of Long Island, New York. The facility, operated by USDA from 1954 and transferred to DHS in 2003, conducted research on foreign animal diseases and — according to Michael Carroll's 2004 book Lab 257: The Disturbing Story of the Government's Secretive Plum Island Germ Laboratory — on tick-borne pathogens. The researcher argument is not necessarily that the Lone Star tick itself was engineered, but that the regional tick-borne-disease landscape was shaped by decades of pathogen research conducted in proximity to mainland tick-range territory.
The Willy Burgdorfer framing. Dr. Willy Burgdorfer (1925–2014), a Swiss-American medical entomologist at the Rocky Mountain Laboratories in Hamilton, Montana, identified the spirochete bacterium responsible for Lyme disease in 1982 — Borrelia burgdorferi, named after him. Science journalist Kris Newby's 2019 book Bitten: The Secret History of Lyme Disease and Biological Weapons documents Burgdorfer's filmed statements in the final years of his life describing his work on US military bioweapon research involving tick-borne pathogens. Newby interviewed Burgdorfer directly and published his documents, including his personal papers, after his death. The researcher framing holds that if the US did conduct tick-weaponization research — as Burgdorfer's documents suggest — the legacy of that research would plausibly manifest across the tick-borne-disease landscape, including but not limited to alpha-gal syndrome.
The vaccine and pharmaceutical framing. Alpha-gal is present in many mammalian-derived medical products, including some vaccine excipients (gelatin stabilizers), certain monoclonal antibodies (cetuximab itself), heparin derivatives, bovine-derived tissue-engineering scaffolds, and various over-the-counter medications. AGS sensitization has implications for these products' safety profiles in affected populations. Some researchers argue the implications have not been adequately addressed by regulatory bodies, particularly as AGS prevalence rises, and that mandatory disclosure of mammalian-derived excipients would benefit patients.
The food-system and climate-agenda framing. That an emerging condition specifically targeting red meat consumption parallels broader cultural and policy pressure to reduce meat consumption for climate reasons — the Netherlands nitrogen regulations, UK meat-reduction messaging, the EU's Farm to Fork Strategy, and the parallel investment in lab-grown meat alternatives by Bill Gates's Breakthrough Energy Ventures and others. Upside Foods (formerly Memphis Meats, received FDA approval for cultivated chicken in 2023), Aleph Farms, and other cultivated-meat companies have received substantial investment from WEF-adjacent networks. The researcher framing holds that the epidemiology of AGS deserves independent examination for whether its acceleration has been instrumentalized alongside policy pressure on conventional meat consumption. It is explicitly a parallel-trajectory observation, not a claim of direct causation — the mainstream ecological explanation for AGS spread (tick range expansion) is not disputed.
The gene-drive and mRNA framing. Adjacent to AGS discussion, researchers have linked the Oxitec Florida Keys mosquito release of 2021–2022 — in which genetically modified Aedes aegypti mosquitoes were released to reduce wild-mosquito populations — to broader questions about deliberate ecological intervention with insect vectors. Yale's 2021 mRNA vaccine against tick bites research, which explored mRNA approaches targeting tick saliva proteins, has further linked AGS-adjacent research to mRNA-era technology platforms. Researchers note these are parallel developments rather than direct connections, but treat them as the broader technology context within which AGS epidemiology should be read.
The ecological-expansion framing (non-conspiracy but adjacent). That the Lone Star tick's range expansion is real, well-documented, and driven by warming winter temperatures plus white-tailed deer population growth; and that AGS is therefore a serious and underrecognized public-health problem warranting significantly more attention and resources than it currently receives. This framing is shared across mainstream and independent research and is the overlap zone where researcher and official framings agree.
The variations
The ecological-expansion framing is widely shared across mainstream and independent research alike — the tick's range is spreading and AGS cases are rising, and there is no serious dispute about the base epidemiology. The pharmaceutical framing is narrower but increasingly mainstream, as the documented alpha-gal content of specific medical products has accumulated in peer-reviewed literature; the question of disclosure and informed consent cuts across both the mainstream and independent frames.
The laboratory-origin framing is a minority researcher position that the CDC and major academic medical centers do not endorse. Within that framing, there is a further split between the weak version — that Plum Island's decades of tick-borne-pathogen research plausibly influenced the regional disease landscape without specific engineering of the Lone Star tick — and the strong version — that specific modification or release is documented by Burgdorfer and others. The climate-agenda overlap framing is held by researchers sympathetic to Agenda 2030 skepticism and tends to be rejected by researchers focused strictly on the biomedical question. The gene-drive framing is held by researchers focused on ecological-intervention technologies more broadly.
What the framings share — the thread that connects researcher attention to AGS — is the observation that the condition is much larger in public-health terms than its public profile reflects, that its rising prevalence has occurred during a period of unusual policy alignment on reducing red meat consumption, and that the adjacent research-program history (Plum Island, Burgdorfer's documented military work, Yale's mRNA tick research) warrants attention that institutional medicine has not given it.
The CDC's Morbidity and Mortality Weekly Report MMWR 72(30), published July 27, 2023 and titled "Geographic Distribution and Expansion of Human Alpha-Gal Syndrome — United States, 2010–2022," reported more than 110,000 suspected AGS cases identified between 2010 and 2022. The CDC estimated actual US prevalence at up to 450,000 people, given substantial underdiagnosis. Documented suspected cases more than doubled between 2017 and 2021. Geographic concentration centers on the Lone Star tick's established range: Virginia, Arkansas, Missouri, Kentucky, Tennessee, with secondary concentration in the Delmarva Peninsula, eastern Texas, and southern Ohio. Case numbers have risen each year reported. The MMWR report was paired with a companion paper on healthcare-provider awareness, which found that 42 percent of surveyed providers had never heard of the syndrome.
In 2024, researchers published the first formally documented death attributed to alpha-gal syndrome in The Journal of Allergy and Clinical Immunology: In Practice, under the title "Implications of a fatal anaphylactic reaction occurring 4 hours after eating beef in a young man with IgE antibodies to galactose-α-1,3-galactose." The patient, a previously healthy young man in New Jersey, developed anaphylaxis approximately four hours after eating beef. The case formally elevated AGS from "chronic nuisance" to "potentially fatal" in the clinical literature. Several additional suspected AGS-related deaths have surfaced in local press and case-report literature since. Severe reactions require epinephrine and can progress rapidly.
The Plum Island Animal Disease Center, located off the northeast tip of Long Island, is an 840-acre federal biocontainment facility. Operated by the US Department of Agriculture from 1954 until its transfer to the Department of Homeland Security in 2003, the facility conducted research on foreign animal diseases including foot-and-mouth, African swine fever, and — per multiple historical accounts — tick-borne pathogens. Its location sits within documented range-expansion vectors for both Lone Star ticks and black-legged (Lyme-vector) ticks; tick dispersal via migratory birds carrying ticks from island to mainland is biologically plausible and has been examined in ornithological literature. Michael Carroll's Lab 257: The Disturbing Story of the Government's Secretive Plum Island Germ Laboratory (2004) is the primary long-form treatment of Plum Island's history. The geographic correlation between Plum Island and emerging-tick-disease clusters has been noted by independent researchers since the 1970s. The facility is scheduled to relocate to the National Bio and Agro-Defense Facility (NBAF) in Manhattan, Kansas, operational since 2023, with Plum Island's decommissioning ongoing.
Willy Burgdorfer (1925–2014) was a Swiss-American medical entomologist at the Rocky Mountain Laboratories in Hamilton, Montana, who identified Borrelia burgdorferi, the Lyme-disease spirochete named after him, in 1982. Science journalist Kris Newby's 2019 book Bitten: The Secret History of Lyme Disease and Biological Weapons — based on direct interviews with Burgdorfer in the final years of his life and on his personal papers published posthumously — documents Burgdorfer's filmed statements describing his participation in US military bioweapon research involving tick-borne pathogens in the 1950s and 1960s. Newby is a former Stanford-based science writer; her book was published by HarperCollins and received substantial mainstream review coverage, including in the Wall Street Journal. Whether the Burgdorfer statements establish, suggest, or merely hint at a military origin or contribution to modern tick-borne-disease prevalence is the researcher-community dispute that Bitten has kept alive.
Save the MMWR, Bitten interviews, and patient testimonials.
The CDC MMWR, the 2024 first-death paper, Kris Newby's Bitten interviews, and the growing archive of AGS patient video testimonials on YouTube and Rumble get rearranged across platforms with some regularity. Michael Carroll's Lab 257 remains available in print but the associated video commentary moves. Classified saves videos locally so you can keep an organized case file of the condition's documented science, the researcher framings, and the lived-experience record.
Download on the App StoreThe connections people make
The AGS researcher framework sits at an unusual intersection of medical science, bioweapon history, food-policy politics, and environmental ecology. Here are the connections most consistently made and the specific events or documents that anchor them.
The Plum Island and the broader tick-borne-disease picture. AGS is one condition within a much broader tick-borne-disease landscape that has expanded substantially in the US over the last three decades. Lyme disease (carried by Ixodes scapularis, the black-legged or "deer" tick) has increased from approximately 10,000 reported cases per year in 1995 to over 50,000 by 2020, with actual prevalence estimated at 10 times that figure. Babesiosis, ehrlichiosis, anaplasmosis, Powassan virus, and heartland virus have all emerged or substantially expanded in the same period. Researchers argue that the cumulative pattern is not adequately explained by warming winters and deer populations alone, and that the Plum Island facility's fifty-year tick-borne-pathogen research history sits within plausible range of the geographic origin of the expansion. The 2024 opening of the Kansas NBAF facility and the ongoing decommissioning of Plum Island mark a generational shift in the federal infrastructure for this research.
The Newby-Burgdorfer documentary record. Kris Newby's Bitten is notable precisely because it is anchored in Burgdorfer's own filmed statements and personal papers, not in secondary interpretation. Newby credentialed herself through prior work on a 2015 Stanford-based Lyme-disease documentary (Under Our Skin) before publishing Bitten. The book was reviewed in the Wall Street Journal, the New York Times, and other mainstream outlets. Its central claim — that Burgdorfer acknowledged working on US military tick-weaponization research — has not been formally rebutted by the Department of Defense or by the Rocky Mountain Laboratories, though neither has confirmed it. The 2019 publication of Bitten was followed by the 2019 Defense Authorization Act provision ordering the DOD Inspector General to investigate whether US military research between 1950 and 1975 "involved the weaponization of ticks and other insects to spread diseases." The Inspector General's report has not been publicly released.
The climate agenda and the meat-alternative industry. The researcher argument here is structural rather than directly causal. AGS makes red meat medically dangerous for an increasing number of Americans. The same decade has seen major investments in alternative-protein infrastructure by WEF-adjacent networks. Upside Foods (formerly Memphis Meats, co-founded by Uma Valeti) received FDA approval for cultivated chicken in 2023 with substantial funding from Bill Gates, Richard Branson, and Cargill. Bill Gates's Breakthrough Energy Ventures has invested in multiple cultivated-meat and plant-based-protein companies. Aleph Farms, Eat Just, Beyond Meat, and Impossible Foods operate within the same ecosystem. The WEF's 2019 "Meat: The Future" series made the case for accelerated transition away from conventional meat consumption. Researchers read the parallel trajectories of AGS epidemiology and alternative-protein policy and capital as worth examining, without necessarily claiming direct causation. The parallel is documented; the connection is contested.
The mRNA tick-saliva research. In 2021, Yale researchers led by Dr. Erol Fikrig published work on an mRNA vaccine targeting tick saliva proteins as a prophylactic approach to tick-borne-disease prevention. The research framed mRNA technology — familiar from the COVID-19 vaccine era — as a platform for intervention in the tick-borne-disease landscape. Independent researchers argue that the technological adjacency between pandemic-era mRNA infrastructure and emerging tick-disease prevention platforms is worth tracking, particularly given the AGS community's concerns about mammalian excipients in existing vaccines and the broader mRNA-platform questions that continue in 2026. Mainstream interpretations treat the Yale research as promising public-health infrastructure.
The gene-drive and Oxitec mosquito releases. The 2021–2022 Oxitec Florida Keys release of genetically modified Aedes aegypti mosquitoes — approximately 750 million modified male mosquitoes released to reduce wild populations of the Zika-vector species — has been cited by researchers as an analogous case of deliberate ecological intervention with disease-vector insects. Oxitec is a UK-based firm. The releases were EPA-approved and locally contested. Researchers argue that the precedent of authorized gene-drive releases changes the interpretive landscape against which AGS and other emerging tick-borne conditions are read: if authorized ecological intervention with disease-vectors is happening openly, the threshold for suspecting similar intervention in historical cases shifts. The Oxitec releases are separate from AGS causally but related as context.
Key voices
- Dr. Thomas Platts-Mills — University of Virginia immunologist; discoverer of the alpha-gal / tick-bite connection (2009 paper); remains the leading academic authority on the syndrome.
- Dr. Scott Commins — University of North Carolina immunologist; co-discoverer with Platts-Mills; one of the principal clinicians managing AGS patients and one of the most frequently quoted academic voices on the condition.
- Tina Hatley Merritt — UVA researcher; third key member of the original discovery team.
- Dr. Jennifer McQuiston — CDC Division of Vector-Borne Diseases; principal investigator on the 2023 MMWR.
- Michael Carroll — author of Lab 257: The Disturbing Story of the Government's Secretive Plum Island Germ Laboratory (2004), the primary long-form treatment of Plum Island's history.
- Kris Newby — science journalist; author of Bitten: The Secret History of Lyme Disease and Biological Weapons (2019), previously a producer on the 2015 Lyme-disease documentary Under Our Skin.
- Dr. Willy Burgdorfer (1925–2014) — medical entomologist who identified Borrelia burgdorferi (Lyme spirochete) in 1982; filmed statements in Newby's Bitten describe his military bioweapon research work.
- Dr. Erol Fikrig — Yale researcher; led the 2021 mRNA tick-saliva vaccine work.
- Alpha-Gal Syndrome Awareness Campaign and Alpha-gal Information (alphagalinformation.org) — patient-advocacy organizations tracking case reports and providing physician-referral resources.
- Candice Matthis — AGS patient advocate; founder of the Tick-Borne Conditions United organization; one of the most visible patient voices in public testimony and media coverage.
For related coverage of emerging-disease origin debates, see our chemtrails and HAARP pages. For the broader policy framework within which the climate-agenda-AGS overlap is read, see Agenda 2030. For the historical pattern of undisclosed institutional planning that the Plum Island framing invokes, see Operation Northwoods.
The official position
The CDC, the American Academy of Allergy, Asthma & Immunology, the National Institute of Allergy and Infectious Diseases, and the mainstream allergy-medicine community recognize alpha-gal syndrome as a tick-borne delayed-type IgE allergy caused by the bite of the Lone Star tick and certain other tick species. The July 2023 MMWR is the most authoritative federal statement on the syndrome's prevalence, geographic distribution, and trajectory. The ecological expansion of the Lone Star tick is attributed to climate warming and white-tailed deer population growth. Laboratory-origin and pharmaceutical-conspiracy framings are not supported by the CDC or major academic medical centers. The Plum Island facility's tick-research history is acknowledged in historical records but is not, in the official framing, connected to contemporary AGS distribution patterns. The Yale mRNA tick-saliva research is characterized as promising public-health infrastructure. The 2019 Defense Authorization Act provision ordering investigation of possible military tick-weaponization research has not produced a publicly-released Inspector General report.
Where it is now
AGS case recognition continues to rise through 2026. The CDC runs an active surveillance effort and has issued extensive physician-education materials. Several state health departments — including Virginia, North Carolina, Tennessee, and Arkansas — have added AGS to reportable-disease lists. Research into desensitization therapies is ongoing at multiple academic medical centers. The 2024 first-documented-death publication and several subsequent case reports have increased mainstream medical attention significantly. The Lone Star tick's geographic range has continued to expand northward through 2025, with established populations now documented in states where AGS was not recognized a decade ago, including parts of New York, Michigan, Wisconsin, and southern New England.
The researcher-community activity has grown substantially. Patient advocacy has become more organized — Candice Matthis's Tick-Borne Conditions United, the Alpha-Gal Syndrome Awareness Campaign, and alphagalinformation.org are among the most-active platforms. The intersection between AGS and the broader Robert F. Kennedy Jr.-era HHS (from January 2025) environmental-health agenda has brought federal political attention to tick-borne diseases that was not present during the Biden administration. Whether that attention translates to new research funding, new regulatory action on mammalian-excipient disclosure, or renewed investigation of the Plum Island historical record is uncertain. The NBAF facility in Kansas is operational; Plum Island is in decommissioning. The institutional landscape is shifting underneath the ecological one.
AGS in 2026 is a condition whose scientific base is stable and accepted, whose public-health profile is rising, whose researcher conversation is unusually substantive and document-anchored, and whose adjacent policy context — from the WHO Pandemic Agreement era through the populist-right health-agenda shift — keeps creating new context for how its questions are read. Whether the condition is understood as purely ecological or partially historical in origin is a question the next federal research cycle and the Inspector General's still-pending report may partially answer.
Go deeper
Primary and secondary sources
- Commins SP, Platts-Mills TA, Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant, Journal of Allergy and Clinical Immunology (2009)
- CDC, MMWR Vol. 72 No. 30, Geographic Distribution and Expansion of Human Alpha-Gal Syndrome — United States, 2010–2022 (July 27, 2023)
- Journal of Allergy and Clinical Immunology: In Practice, "Implications of a fatal anaphylactic reaction occurring 4 hours after eating beef in a young man with IgE antibodies to galactose-α-1,3-galactose" (2024)
- Michael Carroll, Lab 257: The Disturbing Story of the Government's Secretive Plum Island Germ Laboratory (2004)
- Kris Newby, Bitten: The Secret History of Lyme Disease and Biological Weapons (2019)
- Kris Newby and Andrew Abraham (dir.), Under Our Skin (2008) — Lyme-disease documentary
- CDC Alpha-gal Syndrome resource page — cdc.gov/alpha-gal-syndrome
- Alpha-gal Information — alphagalinformation.org — patient resource
- Tick-Borne Conditions United — Candice Matthis's patient-advocacy organization
- 2019 National Defense Authorization Act — Section 1086 on Inspector General investigation of military tick research
- Yale School of Medicine (Fikrig lab), 2021 mRNA tick-saliva vaccine research
- US Environmental Protection Agency, 2021 Oxitec Florida Keys gene-drive mosquito release approvals
Your investigation, organized.
Classified is a private, offline research notebook for independent investigators. Save videos from any platform. Organize arguments and sources into cases. Rate credibility. Present your findings. Everything stays on your iPhone — no account, no cloud, no tracking.
Download on the App StoreFrequently asked questions
What is alpha-gal syndrome?
An IgE-mediated allergy to galactose-alpha-1,3-galactose — a sugar molecule in most non-primate mammal tissues. Triggered by a Lone Star tick bite in most US cases. Causes reactions — hives, GI symptoms, anaphylaxis — when affected individuals consume red meat, dairy, or mammalian-derived medications. Reactions typically delayed 2–8 hours after ingestion.
Who discovered alpha-gal syndrome?
Dr. Thomas Platts-Mills, Dr. Scott Commins, and Tina Hatley Merritt at the University of Virginia, working from 2002; formally established in the 2009 paper in the Journal of Allergy and Clinical Immunology. Originally investigating cetuximab reactions; the tick-bite connection was confirmed in part after Platts-Mills was bitten himself during hiking fieldwork.
What tick causes alpha-gal syndrome?
Primarily the Lone Star tick (Amblyomma americanum) in the US. Identifiable by a single white spot on adult females. Range expanding northward and westward for two decades, attributed to warming winters and white-tailed deer population growth.
How many people have alpha-gal syndrome?
Over 110,000 suspected cases identified between 2010 and 2022 per CDC MMWR 72(30), published July 27, 2023. Estimated actual prevalence up to 450,000 Americans due to underdiagnosis. Documented suspected cases more than doubled between 2017 and 2021.
Has anyone died from alpha-gal syndrome?
Yes. The first formally documented death was published in 2024 in The Journal of Allergy and Clinical Immunology: In Practice — a previously healthy young man in New Jersey who developed anaphylaxis approximately four hours after eating beef. Several additional suspected AGS-related deaths have surfaced since.
What is Plum Island?
The Plum Island Animal Disease Center — an 840-acre US government biocontainment facility off the northeast tip of Long Island. Operated by USDA from 1954, transferred to DHS in 2003. Research on foreign animal diseases and, per multiple historical accounts, on tick-borne pathogens. Michael Carroll's Lab 257 (2004) is the primary long-form treatment. Located within documented range-expansion vectors for both Lone Star and black-legged ticks.
Who was Willy Burgdorfer?
Swiss-American medical entomologist (1925–2014) at the Rocky Mountain Laboratories. Identified Borrelia burgdorferi, the Lyme spirochete named after him, in 1982. Kris Newby's Bitten (2019) documents his filmed late-life statements describing US military bioweapon research involving tick-borne pathogens. The 2019 Defense Authorization Act subsequently ordered an IG investigation of possible military tick-weaponization research; the report has not been publicly released.
Is alpha-gal syndrome man-made?
No mainstream scientific support for a deliberate laboratory origin. The biological mechanism does not require engineered modification. Independent researchers note the geographic overlap between AGS hotspots and the Plum Island facility, cite Burgdorfer's documented military-research statements via Newby, and argue for further investigation. The CDC does not support this framing.
How does alpha-gal syndrome connect to the climate agenda?
AGS removes red meat from affected individuals' diets, paralleling climate-policy pressure on livestock-derived food consumption (Agenda 2030, WEF publications, the Netherlands nitrogen framework) and parallel investment in lab-grown meat (Upside Foods, Memphis Meats, Aleph Farms) by Bill Gates's Breakthrough Energy Ventures and similar networks. Researchers treat the trajectories as worth examining; the parallel is documented, direct causation is not established.
What foods trigger alpha-gal reactions?
Red meat (beef, pork, lamb, venison), products derived from them (gelatin, some dairy), and medications with mammalian excipients (heparin, certain vaccines with gelatin stabilizers, cetuximab and some other monoclonals). Poultry and fish are generally safe. Reactions typically delayed 2–8 hours.